The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
May 14th 2024
Data presented at NKF Spring Clinical Meeting suggest events including myocardial infarction and stroke are more prevalent among patients with lupus in North America.
Lupus Nephritis: TULIP-LN Hints at a Blossoming Role for Anifrolumab
May 10th 2022In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.
From Living BLISSfully to BEATing Lupus: Future Considerations for Biologic Therapy in SLE
May 9th 2022After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.
Rheumatoid Arthritis Quiz: Maximizing the Benefits of at Treat-to-Target Strategy
May 3rd 2022The American College of Rheumatology recommends that a treat-to-target strategy is followed for rheumatoid arthritis. Test your knowledge of how to maximize the potential benefits of this approach with this quiz.
Q&A: Long-Term Safety of Ixekizumab Use in Patients With Psoriatic Arthritis
May 2nd 2022In this Q&A, Gerd R. Burmester, MD, discussed the findings of his study that evaluated the exposure to ixekizumab, outcomes and medical history of patients with active psoriatic arthritis (PsA) who experienced adverse events.
Upadacitinib Receives FDA Approval for Ankylosing Spondylitis
April 30th 2022On April 29, AbbVie announced the US FDA had granted approval to upadacitinib 15 mg (RINVOQ) for treatment of active ankylosing spondylitis among adult patients who had inadequate response or intolerance to at least 1 TNF inhibitor.
How do Rheumatologists Feel About Prescribing Glucocorticoids?
In the interest of receiving a variety of opinions from rheumatologists, we asked several key opinion leaders about their thoughts on treating patients with glucocorticoids, regarding their reputation, benefits, risks, and if they are ultimately more helpful or harmful in the treatment of rheumatic diseases.
Systemic Sclerosis Increases Risk of Adverse Pregnancy Outcomes
“In recent years, the habit of delaying pregnancy because of social and economic reasons has become more common, increasing the possibility of getting pregnant after the onset of the disease," investigators stated. "This fact makes pregnancy a more frequent issue to deal with in the present years.”
Celiac Disease More Prevalent in Patients With Juvenile Idiopathic Arthritis
“Understanding the extent of the co-occurrence and identifying factors associated with an increased susceptibility could be relevant to implement case-finding strategies in specific at-risk populations," investigators stated.